Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Agios Pharm (AGIO)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Agios Pharm's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
33.97 +0.31    +0.93%
10:20:24 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 61,969
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 33.16 - 34.53
Agios Pharm 33.97 +0.31 +0.93%

Agios Pharm Company Profile

 
Get an in-depth profile of Agios Pharm, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

391

Equity Type

ORD

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Contact Information

Address 88 Sidney Street
Cambridge, 02139
United States
Phone 617 649 8600
Fax -

Top Executives

Name Age Since Title
Jacqualyn A. Fouse 61 2017 Chair of the Board of Directors
Brian M. Goff 54 2022 CEO & Director
Kaye I. Foster-Cheek 63 2014 Lead Independent Director
Scott A. Biller 68 2010 Member of Scientific Advisory Board
Matthew Vander Heiden - 2008 Member of Scientific Advisory Board
David P. Schenkein 67 2009 Independent Director
Marc Tessier-Lavigne 64 2011 Member of Scientific Advisory Board
David T. Scadden 71 2017 Independent Director
Cynthia Smith 55 2022 Independent Director
Maykin Ho 71 2015 Independent Director
Charles L. Sawyers 65 2009 Member of Scientific Advisory Board
Ralph Deberardinis - - Member of Scientific Advisory Board
Joan S. Brugge - - Member of Scientific Advisory Board
Rahul D. Ballal 46 2022 Independent Director
Jeffrey D. Capello 59 2023 Independent Director
Catherine E. Owen 53 2023 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

AGIO Comments

Write your thoughts about Agios Pharm
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
MIKHAIL KUZNETSOV
MIKHAIL KUZNETSOV Jan 31, 2022 5:39PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This is Ready for a good run, bought for $30 , I'm waiting for a run to the north, there are catalysts for the near future, with this breakthrough attempt it can go crazy.
Choong Yen
Choong Yen Jun 14, 2021 10:42AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
where is everyone?
Zorro Batman
Zorro Batman Dec 08, 2020 10:04AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what's going on?
Cookie Crumbler
Cookie Crumbler May 07, 2020 7:10PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
why my previous note is dated 2016? I posted it in 2020 May...
andrew mccorkle
andrew mccorkle May 07, 2020 7:10PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
9ok
Jeff Shinn
Alien_Ancestry Oct 10, 2018 12:02PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Again the hyper-selloff!  Reached a low today of 63.56 (at this point).  Biotech has been on a bull run but now in correction.  Start accumulation...
Joel Hanson
Joel Hanson Dec 16, 2016 10:53AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$AGIO Hyper sell off. Get in now. They still have their baby AG-348 which is well tolerated and should succeed with proper regulations.. . Out of 11 analyst, 6 say “buy” 5 say “hold” with an ave 12 month TP of $63.38, a 40.6% ROI.
Cookie Crumbler
Cookie Crumbler Dec 16, 2016 10:53AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
thanks Joel - how much did they pay you to say this? see reality is it went from $46.92  to $36.40 - major loss! should, hopefully, and could matters little
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email